


GUIDELINE FOR MANAGEMENT OF SUSPECTED ICH DURING THROMBOLYSIS DELIVERY



Please Note: Currently there is no evidence that the use of blood products in the acute management of intracranial haemorrhage – related to the use of tenecteplase, secondary haemorrhagic transformation of infarcts or of a primary nature – has any effect on clinical outcomes. This document provides options that may be considered, alongside that of conservative management.